The Gaucher and plant-cell treatment developer is offering a convertible note to US financial institutions.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
-/ By Nadav Neuman /
Protalix Biotherapeutics Inc. (NYSE:PLX; TASE: PLX) announced today that it plans offering a $60 million convertible note to institutional investors in the US repayable in 2018. At the same time the company will also offer a further nine million notes, exercisable 30 days after the pricing date of the notes offering.
Protalix has concluded a range of major deals recently, the most important of which was an agreement with the Brazilian Ministry of Health to provide its Gaucher treatment Uplyso and technology transfer to the Brazilian government to build a factory to produce the drug. The company expects revenue of at least $280 million over the next eight years from this deal.
The Gaucher treatment has US Food and Drug Administration (FDA) approval as Elelyso and is marketed through a commercialization agreement with Pfizer Inc. (NYSE: PFE; LSE: PFZ). However, the treatment has been rejected by the European authorities.
Elelyso is the first plant cell-expressed drug derived from ProCellEx, Protalix’s proprietary plant cell-based protein expression system.
Published by www.globes-online.com